ERBB2 and breast carcinoma: Previous clinical trials have demonstrated the efficacy of HER2‐targeted therapies in non‐breast solid tumors, including biliary tract, non‐small cell lung, colorectal, and bladder cancers,21 and several studies have assessed T‐DM1 in non‐breast cancers.22, 23, 24